While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Sandoz has named its three most promising upcoming biosimilar launches, ahead of filing its proposed high-concentration version of adalimumab with the US Food and Drug Administration.

Sandoz has been able to hike its previously flat full-year annual guidance following an upward trajectory for the company, especially in Europe and the US. One analyst pondered whether this suggested the “emergence of a bottom in the US generics sector” during the second half of the year.